Penka S. Petrova

1.2k total citations
22 papers, 546 citations indexed

About

Penka S. Petrova is a scholar working on Immunology, Surgery and Oncology. According to data from OpenAlex, Penka S. Petrova has authored 22 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 4 papers in Surgery and 3 papers in Oncology. Recurrent topics in Penka S. Petrova's work include Phagocytosis and Immune Regulation (16 papers), Immune cells in cancer (7 papers) and Immunotherapy and Immune Responses (5 papers). Penka S. Petrova is often cited by papers focused on Phagocytosis and Immune Regulation (16 papers), Immune cells in cancer (7 papers) and Immunotherapy and Immune Responses (5 papers). Penka S. Petrova collaborates with scholars based in United States, Canada and United Kingdom. Penka S. Petrova's co-authors include John Kelly, Jeremy C. Smith, Mordechai Anafi, John W. Commissiong, Jonathan Pevsner, Yves Durocher, Amy Peaire, Viji Shridhar, Robert A. Uger and Lisa D. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Penka S. Petrova

22 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Penka S. Petrova United States	9	213	163	139	123	93	22	546
Cheryl D’Souza Canada	13	219 1.0×	106 0.7×	44 0.3×	251 2.0×	147 1.6×	15	687
April Kemper United States	6	119 0.6×	112 0.7×	85 0.6×	188 1.5×	67 0.7×	8	502
Koichi Murakami Japan	13	70 0.3×	107 0.7×	44 0.3×	135 1.1×	101 1.1×	30	495
Luke Oh United States	10	88 0.4×	120 0.7×	50 0.4×	290 2.4×	87 0.9×	11	655
Wolfgang Brueck Germany	10	276 1.3×	55 0.3×	39 0.3×	165 1.3×	62 0.7×	13	634
Woosung Cho United States	9	107 0.5×	68 0.4×	38 0.3×	275 2.2×	56 0.6×	11	514
Dagmar Schütz Germany	12	301 1.4×	69 0.4×	68 0.5×	222 1.8×	250 2.7×	16	619
Axinia Döring Canada	10	244 1.1×	138 0.8×	95 0.7×	198 1.6×	83 0.9×	12	730
Sandra Larouche Canada	8	135 0.6×	89 0.5×	22 0.2×	148 1.2×	50 0.5×	11	467
Julia P. Andreotti Brazil	13	72 0.3×	89 0.5×	49 0.4×	240 2.0×	105 1.1×	15	569

Countries citing papers authored by Penka S. Petrova

Since Specialization

Citations

This map shows the geographic impact of Penka S. Petrova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penka S. Petrova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penka S. Petrova more than expected).

Fields of papers citing papers by Penka S. Petrova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penka S. Petrova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penka S. Petrova. The network helps show where Penka S. Petrova may publish in the future.

Co-authorship network of co-authors of Penka S. Petrova

This figure shows the co-authorship network connecting the top 25 collaborators of Penka S. Petrova. A scholar is included among the top collaborators of Penka S. Petrova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penka S. Petrova. Penka S. Petrova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Querfeld, Christiane, John A. Thompson, Matthew H. Taylor, et al.. (2021). Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. The Lancet Haematology. 8(11). e808–e817. 56 indexed citations

Patel, Krish, Jeffrey A. Zonder, Michael B. Maris, et al.. (2021). CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood. 138(Supplement 1). 3560–3560. 20 indexed citations

Patel, Krish, Radhakrishnan Ramchandren, Michael B. Maris, et al.. (2020). Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood. 136(Supplement 1). 46–47. 14 indexed citations

Viller, Natasja Nielsen, et al.. (2018). Abstract 2720: The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis. Cancer Research. 78(13_Supplement). 2720–2720. 1 indexed citations

Querfeld, Christiane, John A. Thompson, Matthew H. Taylor, et al.. (2018). Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial. Blood. 132(Supplement 1). 1653–1653. 8 indexed citations

Querfeld, Christiane, John A. Thompson, Matthew H. Taylor, et al.. (2017). A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal. Blood. 130. 4076–4076. 15 indexed citations

Diamanti, Paraskevi, et al.. (2017). Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL. Blood. 130. 3886–3886. 1 indexed citations

Thompson, John A., Oleg E. Akilov, Christiane Querfeld, et al.. (2017). A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. Journal of Clinical Oncology. 35(15_suppl). TPS3101–TPS3101. 4 indexed citations

Lin, Gloria H. Y., Hui Chen, Mark Wong, et al.. (2017). Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model. Cancer Research. 77(13_Supplement). 2646–2646. 1 indexed citations

10.

Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2017). TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE. 12(10). e0187262–e0187262. 51 indexed citations

11.

Johnson, Lisa D., Raju Pillai, Rebecca L. King, et al.. (2017). Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.. Journal of Clinical Oncology. 35(7_suppl). 112–112. 3 indexed citations

12.

Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2016). Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages. Cancer Research. 76(14_Supplement). 2345–2345. 1 indexed citations

13.

Diamanti, Paraskevi, et al.. (2016). Investigating the Effects of Anti-CD200 Therapy for Childhood ALL. Blood. 128(22). 4021–4021. 2 indexed citations

14.

Viller, Natasja Nielsen, Emma Linderoth, Lisa D. Johnson, et al.. (2016). Abstract B028: Blockade of the CD47 “Do not eat” signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8+ T cell responses in vitro. Cancer Immunology Research. 4(11_Supplement). B028–B028. 1 indexed citations

15.

Ansell, Stephen M., Robert W. Chen, Ian W. Flinn, et al.. (2016). A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood. 128(22). 1812–1812. 30 indexed citations

16.

Petrova, Penka S., et al.. (2015). Abstract 4271: Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRPαFc, a novel CD47-blocking cancer immunotherapeutic. Cancer Research. 75(15_Supplement). 4271–4271. 1 indexed citations

17.

Uger, Robert A., Karen Dodge, Xinli Pang, & Penka S. Petrova. (2014). Abstract 5011: Cancer immunotherapy targeting CD47: Wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding. Cancer Research. 74(19_Supplement). 5011–5011. 2 indexed citations

18.

Uger, Robert A., Xinli Pang, Mark Wong, et al.. (2013). Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability. Blood. 122(21). 3935–3935. 3 indexed citations

19.

Petrova, Penka S., Jonathan Pevsner, Mordechai Anafi, et al.. (2004). Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Progress in brain research. 146. 167–183. 30 indexed citations

20.

Petrova, Penka S., Jonathan Pevsner, Mordechai Anafi, et al.. (2003). MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons. Journal of Molecular Neuroscience. 20(2). 173–188. 290 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact